Related Experiment Video
Updated: May 24, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Comparative Post-Market Evaluation of Two Generations of Digital Devices for Growth Hormone Therapy: Adherence and
Paul Dimitri1, Lilian Arnaud2, Melissande Simonin3
1Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom.
Abstract:
Adherence to recombinant human growth hormone (r-hGH) therapy is essential for achieving optimal growth outcomes. This retrospective post-market clinical follow-up analysis compared adherence outcomes from real-world device logs of Easypod® 3 (EP3) and Easypod® 2 (EP2). At 12 months, mean adherence was 92.5% (EP3) and 92.4% (EP2), with more than 85% patients maintaining acceptable threshold adherence. These findings support the reliability of device-recorded adherence data and highlight the value of connected injection devices for monitoring adherence with r-hGH therapy and facilitating patient engagement.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Therapeutic Drug Monitoring: Affecting Factors
Drug Products: Biologics, Biosimilars and Interchangeables
Oral Drug Delivery Systems: Continuous-Release Systems
Cellular Adaptation II: Hypertrophy

